Research Collaborations

Brain Health

Multiple Sclerosis (MS)

• Studies exploring performance of Atellica IM Neurofilament Light Chain (NfL) Assay¹ as a prognostic marker in individuals with relapsing MS
• Studies exploring performance of Atellica IM NfL Assay in real-world populations including in diverse local populations across age ranges and in populations with co-pathologies
• Studies to assess the utility of Atellica IM NfL Assay in real-world populations to assess impact on resource utilization, and outcomes for individuals with MS and related decision-making
• Exploratory evidence to support additional medical uses for Atellica IM NfL Assay in individuals with MS (e.g., predicting disease onset, treatment monitoring)
• Treatment algorithm/Medical Guideline-supporting proposals on use of the Atellica IM NfL Assay in individuals with MS

Externally sponsored studies with interventional design and/or involving invasive procedures based on a pre-launch or RUO Atellica assay may not be possible, depending on the local regulatory framework. Proposals will be assessed to define fit with local regulatory compliance. (Prospective blood sample collection only for the purpose of the study is considered an invasive procedure in several regions, incl. EU)

1

Not commercially available in all countries. Available in the U.S. For Research Use Only (RUO) and not for use in diagnostic procedures. Where available as RUO, intended solely to support laboratory research applications and scientific investigation.

Dementia

• Studies exploring performance of Atellica IM Blood Based Markers (BBMs) for differential assessment of adults with memory complaints presenting in a variety of care settings
• Studies exploring performance of Atellica IM BBMs in older adults with memory complaints and common comorbidities
• Studies exploring performance of Atellica IM BBMs across varied sample types
• Exploratory evidence to support use of Atellica IM BBMs to predict rate of progression of dementia
• Exploratory evidence to support use of Atellica IM BBMs for staging of Alzheimer’s Disease (AD)
• Exploratory evidence to support use of Atellica IM BBMs to predict onset of dementia in asymptomatic at-risk individuals
• Head-to-head studies of Atellica IM BBMs assay performance/robustness against competitor tests
• Studies to assess the utility of Atellica IM BBMs in real world populations to assess impact on resource utilization and outcomes for individuals with Dementia, and related decision-making

Other Disease States and Tertiary Areas of Focus

• Studies assessing the utility of Atellica IM BBMs to predict neurological recovery or prognosis in acute neural injury or non-primary neurological disorders or conditions
• Studies to assess the reference ranges for Atellica IM BBMs across different cohorts (e.g., comorbidity-adjusted, pediatric)
• Studies assessing the utility of Atellica IM NfL¹ for use in neuroinflammatory diseases and conditions related to MS or associated with aging

Externally sponsored studies with interventional design and/or involving invasive procedures based on a pre-launch or RUO Atellica assay may not be possible, depending on the local regulatory framework. Proposals will be assessed to define fit with local regulatory compliance. (Prospective blood sample collection only for the purpose of the study is considered an invasive procedure in several regions, incl. EU)

1

Not commercially available in all countries. Available in the U.S. For Research Use Only (RUO) and not for use in diagnostic procedures. Where available as RUO, intended solely to support laboratory research applications and scientific investigation.